** Eli Lilly LLY.N stock climbing 0.1% on Mon after announcing it will ship higher doses of weight-loss drug Zepbound to cash-paying customers starting early Aug
** The modest gain in LLY lagged a ~1% rally in the S&P 500 .SPX, and outperformed a 0.32% dip in the S&P 500 healthcare sector index .SPXHC
** Co to offer 12.5 mg and 15 mg doses on its website for $499/month or less, regardless of insurance status; doctors can prescribe from July 7
** Move aims to counter competition from compounded versions and cheaper copies in the $150 bln obesity drug market
** LLY's stock up about 6% YTD, outperforming S&P 500's ~3% rise
** Stock recently traded at 32x expected earnings, just below its 5-year avg forward PE of 35
** LLY's stock is about 16% below its 52-week intraday high of $972.24 reached on Aug. 27, 2024
(Reporting by Noel Randewich)
((noel.randewich@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.